An evaluation of minor groove binders as anti-Trypanosoma brucei brucei therapeutics by Scott, Fraser J. et al.
Strathprints Institutional Repository
Scott, Fraser J. and Khalaf, Abedawn I. and Giordani, Federica and 
Wong, Pui Ee and Duffy, Sandra and Barrett, Michael and Avery, Vicky M. 
and Suckling, Colin J. (2016) An evaluation of minor groove binders as 
anti-Trypanosoma brucei brucei therapeutics. European Journal of 
Medicinal Chemistry, 116. pp. 116-125. ISSN 0223-5234 , 
http://dx.doi.org/10.1016/j.ejmech.2016.03.064
This version is available at http://strathprints.strath.ac.uk/56083/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (http://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any  correspondence  concerning  this  service  should  be  sent  to  Strathprints  administrator: 
strathprints@strath.ac.uk
Research paper
An evaluation of Minor Groove Binders as anti-Trypanosoma brucei
brucei therapeutics
Fraser J. Scott a, *, Abedawn I. Khalaf a, Federica Giordani b, Pui Ee Wong b, Sandra Duffy c,
Michael Barrett b, Vicky M. Avery c, Colin J. Suckling a
a WestCHEM Department of Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow G1 1XL, United Kingdom
b Wellcome Trust Centre for Molecular Parasitology, Institute of Infection, Immunity and Inﬂammation and Glasgow Polyomics, College of Medical,
Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, United Kingdom
c Discovery Biology, Eskitis Institute for Drug Discovery, Grifﬁth University, Nathan, Queensland 4111, Australia
a r t i c l e i n f o
Article history:
Received 19 November 2015
Received in revised form
21 March 2016
Accepted 23 March 2016
Available online 29 March 2016
Keywords:
Minor Groove Binders
Antiparasitic activity
African trypanosomiasis
a b s t r a c t
A series of 32 structurally diverse MGBs, derived from the natural product distamycin, was evaluated for
activity against Trypanosoma brucei brucei. Four compounds have been found to possess signiﬁcant ac-
tivity, in the nanomolar range, and represent hits for further optimisation towards novel treatments for
Human and Animal African Trypanosomiases. Moreover, SAR indicates that the head group linking
moiety is a signiﬁcant modulator of biological activity.
© 2016 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
In the last few decades there has been a signiﬁcant increase in
the amount of research directed at developing treatments for Af-
rican trypanosomiasis and although few new drugs have emerged,
notable progress has been made [1]. For example, 2009 saw the
launch of a nifurtmox/eﬂornithine combination therapy for use
against T. b. gambiense [2]. Drug design strategy towards African
trypanosomiasis is currently undergoing a shift with an emphasis
on new targets. N-Myristoyl transferase has recently been sug-
gested as a potential molecular target for development after iden-
tiﬁcation through target-based approaches [3]; however, a number
of other similarly identiﬁed targets have not proven effective in-
dicators of activity in in vivo experiments [4]. Consequently more
effort has been placed on phenotypic screening and notable out-
comes include oxaborole SCYX-7158, in phase I clinical trials, and
fexinidazole, which is in phase III [5].
Minor Groove Binders (MGBs) have been used against
trypanosomiasis since the 1930s; in particular the bisamidines
pentamidine and diminazene (Fig. 1) have been used as ﬁrst-line
treatments for Human African Trypanosomiasis (HAT) and Animal
African Trypanosomiasis (AAT), respectively [6]. Many hundreds of
related compounds have been synthesised and evaluated against
trypanosomiasis and, additionally, many have found uses against
protozoan infections, including leishmaniasis and malaria [7].
Although extensively investigated, the actual mechanism of
action of MGBs in protozoa remains unclear and it is likely to differ
in different species [8,9]. It has been demonstrated that pentami-
dine, furamidine (Fig. 1), and a number of other diamidines are
actively transported into both trypanosomes and plasmodia,
achieving high intracellular concentrations. Moreover, these com-
pounds bind strongly to AT-rich sites of the minor groove of para-
sitic DNA [8,10]. Furamidine, for example, binds to an AT rich DNA
oligonucleotide with KD in the 100 nM range [10].
DNA binding as the proposed mechanism of action is
strengthened considering that DNA binding correlates to some
extent with trypanocidal activity [9e11]. The kinetoplast mini-
circles of trypanosomes are particularly AT-rich and thus present a
likely target for diamidines. Furthermore, destruction of the
kinetoplast has been observed within 24 h’ exposure to pentami-
dine and furamidine, leading to the death of the trypanosome [12]
and in leishmania too loss of kinetoplast precedes death [13].
Although much effort continues towards the development of novel
anti-protozoal diamidines, including clinical and preclinical trials
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[14], the problem of cross-resistance with current treatments re-
mains. For example, mutations in the transporters involved in
cellular drug accumulation have been implicated in pentamidine
resistance [15].
At Strathclyde we have developed a collection of MGBs which
are structurally based on the natural product distamycin. This
compound is built from N-methylpyrrole amino acid amides and
has an amidine end group (Fig. 2). In developing MGBs at Strath-
clyde, we modiﬁed a number of the regions of the prototype
structure. Less basic functional groups have been introduced to
replace the amidine at the C-terminus (usually referred to as the tail
group because of its ﬂexibility). Larger alkyl side chains have been
substituted for methyl groups and thiazole rings have been intro-
duced to the body of the MGB. Additionally, aromatic rings have
replaced the formyl group from distamycin and the N-terminal
amide has been replaced by its isosteric alkene [16,17]. Although
the structures of Strathclyde MGBs now differ substantially from
the parent compound, distamycin, the preferential binding to AT-
rich DNA, over GC, still remains for this class of compound in
general [18].
In conjunction with our commercial partner, MGB Biopharma,
we have had great success in developing our MGBs as antibacterials
[18] and, crucially, structural features of these MGBs are quite
distinct from the diamidines. For example, the terminal amidine
groups that are critical to both activity and uptake of the diamidines
are absent in these antibacterial distamycin analogues. Since loss of
transport seems to underlie resistance to diamidines, it seems likely
that crosseresistance to the Strathclyde MGBs would not occur
should they be active. With new drugs a priority for both human
and veterinary trypanosomiases, we have investigated our MGBs as
potential antitrypanosomal agents. This study thus reveals our
exploratory investigation and ﬁndings of Strathclyde MGB activity
against Trypanosoma brucei brucei as a representative and relevant,
initial target parasite. The results identify lead compounds with the
potential for optimisation and development.
2. Results and discussion
2.1. Synthesis
The MGBs investigated in this study possess two locations of
diversity when considering their synthesis: the head group link and
the number of heterocycles. The head group is linked by an amide,
an amidine, or an alkene and the number of heterocycles between
the head and the tail group is either two or three (Fig. 3). This set of
compounds allows us to assess some key structural points with
respect to the design of MGBs as antitrypanosomal agents.
Synthesis of these MGBs (Scheme 1) was achieved in a modular
fashion, initially building from the C-terminus, tail group end, of
the molecule and ending with a coupling reaction to attach the
head group. To build a thiazole-containing MGB, the acid chloride
of the nitropyrrole carboxylic acid was made using thionyl chloride,
followed by reacting with the methyl 2-amino-5-alkyl-1,3-
thiazole-4-carboxylate. The methyl ester of the carboxylic acid
was hydrolyzed using LiOH in water/methanol before an HBTU
coupling was employed to attach the primary amine of the tail
group to the carboxylic acid of the thiazole containing dimer. The
nitro group of the N-terminus was reduced to an amine by hy-
drogenation using palladium over charcoal and a further pyrrole
was attached by using thionyl chloride to prepare the corre-
sponding acid chloride. For pyrrole-only containing MGBs, the tail
group was attached to a pyrrole heterocyclic unit ﬁrst. This was
achieved by forming the acid chloride of the nitropyrrole carboxylic
acid using thionyl chloride, followed by reacting with the appro-
priate tail group amine. Further pyrrole heterocyclic units were
added as necessary using the same coupling method and reducing
the nitro group to an amine as previously described. The ﬁnal step
to form the complete MGB depended on the particular link to the
head group.
The ﬁnal coupling to form the MGBs with an amide linked head
group was carried out using HBTU. To do this, the nitro group of the
appropriate tail group containing dimer or trimer was ﬁrst reduced
and reacted, without further puriﬁcation, with the required head
group carboxylic acid which had been charged with HBTU. Before
the ﬁnal coupling to form the alkene containing MGBs, the
appropriate head group was ﬁrst synthesised using a Hor-
nereWadswortheEmmons reaction, as previously described [19].
As before, HBTU coupling was used to attach the head group to
form the alkene containing MGB. Those MGBs with amidine linked
head groups were prepared using a methyl imidothiolate head
group. Brieﬂy, the commercially available nitriles were converted
Fig. 1. Bisamidine antitrypanosomal compounds.
Fig. 2. Distamycin and an example Strathclyde MGB. Fig. 3. Exemplars of the types of MGB investigated in this study.
F.J. Scott et al. / European Journal of Medicinal Chemistry 116 (2016) 116e125 117
into the corresponding thioamides by the use of thioacetamide. The
thioamide was then reacted with methyl iodide in order to afford
required methyl imidothiolate head groups. To form the amidine
containing MGB the nitro group of the appropriate tail group
containing trimer was reduced, as before, and reacted with one
equivalent of the appropriate methyl imidothiolate head group.
All MGBs were puriﬁed by HPLC to give a ﬁnal purity greater
than 98%. Table S1 in the supplementary information shows the
structures of the MGBs that were investigated in this study.
2.2. Biological activity
The majority of the MGBs investigated in this study display
appreciable activity against T. b. brucei in the range of 0.1e2 mM
(Table 1); however, close inspection of the structural types in-
dicates that the amidine linked head group MGBs (1, 2, 5, 9, 17, 19)
are not strongly active. The most active of these, 17 and 19, have an
IC50 of 4.9 and 2.2 mM respectively, whilst the other amidine linked
head group compounds, 1, 2, 5, 9 all have IC50s greater than 75 mM.
More evidence for the poor tolerance of a basic site in the head
group end can be seen in comparing compounds 20 and 23. Here,
the removal of the basic site of the quinoline, through using the
naphthalene, results in the IC50 decreasing from 0.62 mM to 40 nM.
The data also reveal that the set of shorter MGBs, 14, 15 and 18,
retain activity against T. b. brucei and are comparable in activity to
many of the longer MGBs. These compounds have IC50 values of
0.97, 2.2 and 0.39 mM respectively, which places them within the
range of activity of most of the MGBs. This is an important point as
the shorter length MGB could be anticipated to bind to DNA less
strongly due to lower potential for stabilising van der Waals’
interactions.
A tentative conclusion can also be drawn in examining the effect
Scheme 1. Synthetic strategy for MGBs. (i) Thionyl chloride, 50 C, 4 h, then amine in DCM, rt, overnight, 43e60%; (ii) LiOH, MeOH:water (5:1), 48 h, 92e96% (iii) H2, Pd/C, MeOH, rt,
2 h, used immediately in next step; (iv) HBTU, DMF, rt, overnight, 95%; (v) DMF, rt, overnight, 14e64%. Compound numbers beneath structures refer to general synthetic methods in
experimental section.
Table 1
Activities against Trypanosoma brucei brucei. Where N/A is an IC50 > 75 mM and all
standard deviations are less than 2%. Diminazene positive control has an IC50 of 5 nM
*Compounds determined to have signiﬁcant activity.
Compound IC50 (mM) Compound IC50 (mM)
1 N/A 17 4.9
2 N/A 18 0.39
3 0.40 19 2.2
4 48 20 0.040*
5 N/A 21 0.0054*
6 4.0 22 0.73
7 27 23 0.62
8 0.0068* 24 0.38
9 N/A 25 2.3
10 0.30 26 0.71
11 0.28 27 0.22
12 0.18 28 0.0073*
13 0.21 29 0.019*
14 0.97 30 0.63
15 2.2 31 5.0
16 0.79 32 0.17
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of the tail group on activity by considering the compound pairs 14
and 15, and 13 and 21. These are matched pairs in which the mol-
ecules only differ by containing either morpholine or dimethyl-
amine in the tail group. In both cases, the less basic morpholine tail
group leads to greater activity as is particularly noticeable for
compounds 13 and 21 where the activity dramatically increases
from 0.21 mM to 5.4 nM.
Of great signiﬁcance is the discovery of ﬁve compounds with
IC50 values of less than 40 nM. Four of these compounds (20, 21, 28
and 29) belong to the alkene linked head group set, and the other
(compound 8) belongs to the amide linked head group set, The IC50
of the diamidine control, diminazene, in this assay is 5 nM and
compounds 8, 21 and 28 come particularly close to this with IC50
values of 6.8, 5.4 and 7.3 nM, respectively.
The ﬁve most active compounds were evaluated for their
mammalian cytotoxicity using an AlamarBlue® viability assay us-
ing the human embryonic kidney cell line, HEK 293. These results
are shown in Table 2.
Of these compounds, only 21 had a measureable cytotoxicity at
the 20 mM test concentration. Furthermore, these ﬁve most active
compounds all displayed selectivity indices at least greater than
500 indicating substantial parasite selectivity. From these data, 8
and 28 appear particularly attractive as candidates for lead opti-
misation due to their selectivity indices of >2941 and > 2739,
respectively.
2.3. In silico physicochemical properties prediction
A number of standard physicochemical properties were pre-
dicted using the software MarvinSketch (Version 15.6.29.0,
ChemAxon, http://www.chemaxon.com), in an attempt to gain
some insight into the differences in activity. Full details of these can
be found in the supplementary electronic information; however, a
representative selection is presented here for discussion. Fig. 4
depicts the relationship between the calculated logD7.4 and the
log of the activity, which shows a weak negative correlation be-
tween the two. This relationship holds for logD estimates at pHs
6.5, 5.0 and 1.5 also (see supplementary information).
Fig. 5 shows the data grouped by head group type, with separate
correlation coefﬁcients, and suggests that the three head group
types have different characteristics with respect to this measure of
correlation. Moreover, the four most active compounds appear to
be outliers (orange squares in Fig. 4) suggesting that some speciﬁc
interactions with a component of the target organism might be
responsible for the high activity.
It is possible that speciﬁc biological transporters are important
in determining the activity of these compounds rather than passive
transport across membranes. A speciﬁc example of this would be in
the comparison of compounds 27 and 28 which have IC50 values of
0.22 mM and 7.3 nM, respectively. Both of these compounds have
the same predicted values of logD across pHs 1.5, 5.0, 6.5 and 7.4
and so would be expected to have the same membrane perme-
abilities, yet their activities signiﬁcantly differ. Similarly, the lack of
activity for most of the amidine linked head group MGBs may be
due to a speciﬁc biological event, such as increased cellular efﬂux
(or decreased inﬂux).
Compound 8 (IC50 ¼ 6.8; logD7.4 ¼ 1.9) would appear from the
above analysis to be the most attractive compound for medicinal
chemical optimisation. LogD7.4with this template could be lowered
by increasing the pKa of the tail group or by introducing a more
polar head group such as those of the active alkenes, 28 and 29. The
least lipophilic active alkene, 29 (IC50¼ 19 nM; logD7.4¼ 3.2), is also
in a suitable property range to be a lead for optimisation. Such
optimisation in the next stage of the project will necessarily involve
consideration of pharmokinetic, metabolic, and toxicity properties
but the intrinsic ﬂexibility of the Strathclyde MGB template allows
for great structural variety to be introduced.
Table 2
Activities against HEK 293 cells and Trypanosoma brucei brucei. Where N/A is an IC50 value > 20 mM. The Puromycin control had an IC50of 350.5 nM (±2.12) from two separate
independent experiments. *Calculation of selectivity index (SI) was made using 20 mM as the IC50 value for HEK 293 cells in all cases apart from compound 21 where an
estimated IC50 of 10 mM was made based on an average of 54% inhibition at 20 mM.
Compound % HEK 293 Inhibition at 20 mM Trypanosoma brucei brucei IC50 (mM) SI*
8 N/A 0.0068 >2941
20 N/A 0.040 >500
21 54 0.0054 >1851*
28 N/A 0.0073 >2739
29 N/A 0.019 >1052
R² = 0.3548
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Fig. 4. LogD7.4 against MGB activity. Orange squares indicate the most active com-
pounds. (For interpretation of the references to colour in this ﬁgure legend, the reader
is referred to the web version of this article.)
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Fig. 5. LogD7.4 against MGB activity grouped by head group link.
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2.4. Fluorescence microscopy
To investigate DNA binding as a plausible mechanism of action
for this series of MGBs, compound 32, which is strongly ﬂuorescent
although not highly active, was used to study intracellular local-
isation by ﬂuorescence microscopy (Fig. 6). This experiment
conﬁrmed internalisation of compound 32 into the trypanosome,
where localisation to the nucleic acid rich regions of the nucleus
and kinetoplast was observed. In addition to these, a punctate
staining pattern of unknown originwas visible under both FITC and
DsRed ﬁlters.
The localisation of an MGB in organelles other than those rich in
nucleic acids is of interest to understand their mechanism of action.
In the ﬁeld of MGBs as antibacterials, it has been suggested that
DNA binding may not be the only mechanism leading to antibac-
terial activity [20]. However, although other cellular targets may
exist, interference with DNA centric events are still thought to be
the most mechanism of action of these MGBs against
trypanosomes.
3. Conclusion
In this study we have demonstrated that our MGBs possess
activity against T. b. brucei. Furthermore, ﬁve compounds have been
identiﬁed as leads for future investigation, each with IC50 values
lower than 40 nM. The spectrum of activities that have been
observed would suggest that speciﬁc biological transporters are
involved in MGB uptake and not only passive transport across
membranes e the head group link being of principal importance.
Designing selective antimicrobials is of importance in attempt-
ing to curtail the increase in antimicrobial resistance and this study
has also contributed some new knowledge to our antibacterial MGB
design. All the MGBs in this study are known to possess a range of
antibacterial activity [19, unpublished data]; however, this study
has revealed that focusing our investigation on those with amidine
linked head groups may allow the development of antibacterials
without antitrypanosomal activity.
Furthermore, we have demonstrated that DNA remains a
possible target for these MGBs in trypanosomes similar to the case
for bacteria.
4. Experimental
4.1. Biological activity
4.1.1. Trypanosoma brucei brucei assay
Bloodstream form T. b. brucei (Lister 427) was cultivated in HMI-
9 medium (Gibco) supplemented with 10% heat inactivated FBS
(Gibco), at 37 C in a humidiﬁed 5% CO2 environment. IC50 values
against trypanosomes were determined by Alamar Blue assay.
Brieﬂy, 2 104 cells/mL were seeded into serial dilutions of the test
compounds and incubated for 48 h at 37 C, 5% CO2. After this time,
20 mL of resazurin dye (SigmaeAldrich) solution at 0.49 mM was
added. Following further 24 h incubation the reduction of resazurin
was measured using a ﬂuorimeter (FLUOstar Optima, BMG Labtech)
at 544 nm excitation and 590 nm emission wavelengths. Output
was plotted using the IC50 determination algorithm of Prism 5.0
software (GraphPad). Three independent experiments were carried
out in duplicate for each compound.
4.1.2. HEK 293 cytotoxicity assay
Compounds were tested in an AlamarBlue viability assay using
ﬂuorescent intensity as the output. Brieﬂy, Human Embryonic
Kidney cells (HEK 293) were cultured in DMEM (Dulbeccos Modi-
ﬁed Eagle Medium) plus 10% Foetal Bovine Serum (FBS) in a hu-
midiﬁed environment at 37 C and 5% CO2. Cells were harvested at
80% conﬂuence and plated into 384-well tissue culture treated
black walled clear base plates at 2000 cells per well in a volume of
45 ml and incubated overnight to equilibrate. Five ml of compounds
in serial dilution format, including Puromycin as a positive control
and 0.4% DMSO as the negative control, were transferred into the
plates containing the equilibrated HEK293 cells. The plates were
incubated for a further 72 h before “ﬂicking” the compound con-
taining media out and replacing with 40 mL of 10% AlamarBlue® in
DMEM without FBS. The assay plates were returned to the incu-
bator for 6 h then the total ﬂuorescent intensity determined at
535 nm excitation and 585 nm emission using the Perkin Elmer
ENVISION 2101 Multilabel Reader. Fluorescent intensity values
were normalized as percent inhibition in relation to the positive
and negative controls of 5 mM Puromycin and 0.4% DMSO, respec-
tively. The compounds were tested in two separate experiments
each in duplicate point.
4.2. Fluorescence microscopy
T. b. brucei parasites (1  107 cell/mL) were treated with 50 mM
of compound 32 for 2 h at 37 C in a humidiﬁed, 5% CO2 atmo-
sphere. After washing in PBS, an aliquot of cells was mixed with an
equal volume of 2% w/v lowmelting point agarose (SigmaeAldrich)
and spread onto a slide by addition of a coverslip. Slides were
viewed using a Zeiss Axioplan 2 Imaging epiﬂuorescence micro-
scope, equipped with a digital CCD camera (Hammatsu Photonics)
and a PlanNEUFLUAR 100  oil-immersion NA 1.4 objective (Carl
Zeiss). FITC (excitation 450e490 nm, beamsplitter 510 nm, emis-
sion 515e565 nm) and DsRed (excitation 545/25 nm, beamsplitter
570 nm, emission 605/70 nm) ﬁlter sets were used, and images
acquired using Volocity imaging software (Improvision).
Fig. 6. Intracellular localisation of ﬂuorescent MGB in T. b. brucei. Trypanosomes were treated for 2 h with 50 mM of MGB and viewed at 100  magniﬁcation. N ¼ nucleus;
K ¼ kinetoplast; arrow ¼ other organelles. Bar ¼ 10 mm.
F.J. Scott et al. / European Journal of Medicinal Chemistry 116 (2016) 116e125120
4.3. Synthesis
4.3.1. General experimental methods
1H and 13C NMR spectra were measured on a Bruker DPX-
400 MHz spectrometer with chemical shifts given in ppm (d-
values), relative to proton and carbon traces in solvent. Coupling
constants are reported in Hz. IR spectra were recorded on a Perkin
Elmer, 1 FT-IR spectrometer. Mass spectra were obtained on a Jeol
JMS AX505. Anhydrous solvents were obtained from a Puresolv
puriﬁcation system, from Innovative Technologies, or purchased as
such from Aldrich. Melting points were recorded on a Reichert hot-
stage microscope, and are uncorrected. Chromatography was car-
ried out using 200e400 mesh silica gels, or using reverse-phase
HPLC on a waters system using a C18 Luna column.
4.3.2. General synthesis of pyrrole monomer with tail group
1-Methyl-4-nitro-1H-pyrrole-2-carboxylic acid (500 mg,
2.94 mmol) was suspended in thionyl chloride (5 mL) then the
reaction mixture was heated under reﬂux for 4 h. Excess thionyl
chloride was removed under reduced pressure at 50 C and the acid
chloride so formed was dissolved in DCM (5 mL, dry) and trime-
thylamine (2.94 mmol) was added. To this was added the appro-
priate primary amine containing tail group (2.94 mmol) in DCM
(1 mL). The addition was dropwise with stirring and the stirring
was continued overnight. The solvent was removed under reduced
pressure and the crude product was puriﬁed by column chroma-
tography using methanol/ethyl acetate (1/4) containing 1% TEA.
Fractions containing the product were collected and the solvents
were removed under reduced pressure to give the pure product.
4.3.3. General synthesis of dimers
4.3.3.1. Thiazole methyl ester dimer.
1-Methyl-4-nitro-1H-pyrrole-2-carboxylic acid (500 mg,
2.94 mmol) was suspended in thionyl chloride (5 mL) then the
reaction mixture was heated under reﬂux for 4 h. Excess thionyl
chloride was removed under reduced pressure at 50 C and the acid
chloride so formed was dissolved in DCM (5 mL, dry). The appro-
priate 2-aminothiazole methyl ester (3.19 mmol) was dissolved in
DCM (5 mL, dry) to which triethylamine (0.5 mL, dry) was added
with stirring at room temperature. The acid chloride solution was
added to the amine solution dropwise with stirring at room tem-
perature and the stirring was continued overnight. The reaction
mixturewas extracted with KOH solution (840mg, inwater 10 mL).
The organic layer was extracted with brine, dried (MgSO4) and the
solvent removed under reduced pressure. The crude product was
applied to a column chromatography using silica gel and ethyl
acetate/n-hexane as eluant (1/4) to afford the desired product.
4.3.3.2. Thiazole carboxylic acid dimer. The thiazole methyl ester
dimer (1.74 mmol) was suspended in a mixture of water (25 mL)
and methanol (5 mL) containing lithium hydroxide (125 mg,
5.21 mmol). The reaction mixture was stirred vigorously for 48 h at
room temperature. Some of the methanol was removed under
partial reduced pressure at 50 C. The cooled solutionwas extracted
with ether and the ethereal layer was discarded. The aqueous layer
was cooled to 0 C and acidiﬁed by adding HCl (Concentrated)
dropwise with stirring. The pale yellow solid was ﬁltered off,
washed with water and dried overnight at 45 C under reduced
pressure to give the required material.
4.3.3.3. Thiazole containing dimer with tail group. The thiazole
carboxylic acid dimer (1.56 mmol) was dissolved in DMF (2.5 mL,
dry) to which thiethylamine (0.5 mL, dry), HBTU (1.18 g, 3.12 mmol)
and the appropriate primary amine containing tail group
(3.12 mmol) were added at room temperature with stirring. Ethyl
acetate and dilute sodium hydroxide solutionwere added. After the
extraction, the organic layer was collected, dried (Na2SO4), ﬁltered
and the solvent was removed under reduced pressure. The crude
product was applied to a silica gel column and eluted with ethyl
acetate/methanol (1/1) containing 1% TEA. Fractions containing the
required product were collected and the solvents were removed
under reduced pressure to give the desired product.
4.3.3.4. Pyrrole-only containing dimer with tail group. The appro-
priate pyrrole monomer with tail group (1.06 mmol) was dissolved
in methanol (25 mL) to which Pd/C-10% (135 mg) was added. The
reaction mixture was hydrogenated for 3 h at room temperature
and atmospheric pressure. The catalyst was removed over Kiesel-
guhr and the solvent was removed under reduced pressure. The
amine so formed was dissolved in DCM (2 mL, dry), to which
triethylamine (0.3 mL) was added. 1-Methyl-4-nitro-1H-pyrrole-2-
carboxylic acid (181 mg, 1.06 mmol) was suspended in thionyl
chloride (2 mL), and heated under reﬂux for 2 h. Excess thionyl
chloride was removed under reduced pressure to give the acid
chloride, which was dissolved in DCM (2mL, dry). The acid chloride
solution was added dropwise to the amine solution at room tem-
perature with stirring. The stirring was continued overnight. The
reaction mixture was extracted with potassium hydroxide solution
(KOH 588mg inwater 10mL). The organic layer was dried (MgSO4),
the solved was removed under reduced pressure and the crude
product was puriﬁed by column chromatography, methanol/ethyl
acetate (1/4) containing 1% TEA to give the required product.
4.3.4. General synthesis of trimer
The appropriate dimer (0.65 mmol) was dissolved in methanol
(25 mL) to which Pd/C-10% (150 mg) was added. The reaction
mixture was hydrogenated for 4 h at room temperature and at-
mospheric pressure. The catalyst was removed over Kieselguhr and
the solvent was removed under reduced pressure. The amine so
formed was dissolved in DCM (2 mL, dry), to which triethylamine
(0.3mL) was added.1-Methyl-4-nitro-1H-pyrrole-2-carboxylic acid
(0.65 mmol) was suspended in thionyl chloride (2 mL), and heated
under reﬂux for 2 h. Excess thionyl chloride was removed under
reduced pressure to give the acid chloride, which was dissolved in
DCM (2 mL, dry). The acid chloride solution was added dropwise to
the amine solution at room temperature with stirring. The stirring
was continued overnight. The reaction mixture was extracted with
potassium hydroxide solution (KOH 588 mg in water 10 mL). The
organic layer was dried (MgSO4), the solved was removed under
reduced pressure and the crude product was puriﬁed by column
chromatography using methanol/ethyl acetate (1:5) containing 1%
TEA to give the required product.
4.3.5. General synthesis of alkene head group
4.3.5.1. Head group methyl ester. The appropriate dieth-
ylphosphonate (1.15 mmol) was dissolved in THF (5 mL, dry) then
cooled to 0 C under nitrogen. Sodium hydride (92 mg, 60% sus-
pension in oil, 2.30mmol) was added portionwisewith stirring. The
appropriate aldehyde (1.15 mmol) was dissolved in THF (5 mL, dry)
then added to the reaction mixture at 0 C under nitrogen with
stirring. The reaction mixture was then left stirring at room tem-
perature for 1 h.Water was added at 0 C, dropwise, under nitrogen
followed by dilute HCl until pH 6. The reaction mixture was diluted
with ethyl acetate and extracted. The water layer was extracted
oncemorewith ethyl acetate and the combined organic layers were
dried (MgSO4), ﬁltered and the solvents were removed under
reduced pressure. The product was puriﬁed by column chroma-
tography using ethyl acetate/n-hexane (1:2) to give the required
methyl ester of the head group.
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4.3.5.2. Head group carboxylic acid. The methyl ester of the head
group (0.32 mmol) was dissolved in methanol (5 mL) to which
sodium hydroxide solution (NaOH 200 mg, 5 mmol inwater 10 mL)
was added. The reaction mixture was heated under reﬂux for 3 h.
Methanol was removed under partial reduced pressure and the
remaining solution was cooled to 0 C. Hydrochloric acid (conc.)
was added dropwise with vigorous stirring until pH 4. The material
was collected by ﬁltration, washed with water and dried under
reduced pressure at 50 C to give the required material.
4.3.6. General synthesis of head group for amidine linked MGB
The appropriate thioamide (0.55 mmol) was suspended in
acetone (25 mL, dry) to which iodomethane (200 mL) was added
and the reaction mixture was heated under reﬂux for 6 h and the
product was ﬁltered off, washed with small amount of dry acetone
and dried under reduced pressure at 45 C overnight to give the
required product.
4.3.7. General synthesis of alkene or amide MGB
The tail group containing dimer or trimer (0.266 mmol) was
dissolved in methanol (25 mL), to which Pd/C-10% (60 mg) was
added at 0 C under nitrogen with stirring. The reaction mixture
was hydrogenated at room temperature and atmospheric pressure
for 4 h. The catalyst was removed over Kieselguhr and the solvent
was removed under reduced pressure to give the amine, which was
dissolved in DMF (1 mL, dry). The appropriate head group car-
boxylic acid (0.266 mmol) was dissolved in DMF (1 mL, dry) to
which HBTU (260 mg, 0.685 mmol) and triethylamine (50 mL) were
added to the reaction mixture at room temperature with stirring
and the reaction mixture was left standing at room temperature
overnight. The product was puriﬁed byHPLC (nowork up required).
Fractions containing the product were collected and freeze dried to
give the required product.
4.3.8. General synthesis of amidine linked MGB
The tail group containing trimer (0.401 mmol) was dissolved in
methanol (25 mL), cooled to 0 C then Pd/C-10% (135 mg) was
added with stirring. The reaction mixture was hydrogenated for 4 h
at room temperature and atmospheric pressure. The catalyst was
removed over Kieselguhr and to this was added the hydrogen io-
dide salt of the appropriate methyl imidothiolate (0.26 mmol) at
room temperature with stirring, and then the reaction mixture was
kept at room temperature for 48 h. Solvent was removed under
reduced pressure and the product was puriﬁed by HPLC (no work
up required). Fractions containing the product were collected and
freeze dried to give the required product.
4.3.9. N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-
methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-
4-{[imino(phenyl)methyl]amino}-1-methyl-1H-pyrrole-2-
carboxamide 1
Prepared as per [19].
4.3.10. N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-
methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-
4-(ethanimidoylamino)-1-methyl-1H-pyrrole-2-carboxamide 2
Prepared as per [19].
4.3.11. 4-[(2,4-Dichlorobenzoyl)amino]-1-methyl-N-[1-methyl-5-
({[1-methyl-5-({[2-(4-morpholinyl)ethyl]amino}carbonyl)-1H-
pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]-1H-pyrrole-2-
carboxamide 3 (synthesis also reported in [23])
White solid (34mg, 41%) with no distinct melting point. 1HNMR
(DMSO-d6): 10.48 (1H, s), 9.94 (1H, s), 9.91 (1H, s), 9.53 (1H, br),
8.21 (1H, t, J ¼ 5.5 Hz), 7.74 (1H, d, J ¼ 1.7 Hz), 7.55e7.53 (2H, m),
7.26 (1H, d, J¼ 1.7 Hz), 7.23 (1H, d, J¼ 1.7 Hz), 7.19 (1H, d, J¼ 1.7 Hz),
7.07 (1H, d, J ¼ 1.7 Hz), 7.02 (1H, d, J ¼ 1.7 Hz), 7.00 (1H, d,
J ¼ 1.7 Hz), 3.99 (2H, m), 3.87 (3H, s), 3.85 (3H, s), 3.82 (3H, s),
3.53e2.99 (10H, m). IR (KBr): 1665, 1550, 1290, 1200, 1131 cm1.
HRFABMS: found: 669.2112 calculated for C31H35Cl2N8O5 669.2107.
4.3.12. 4-(Formylamino)-1-methyl-N-[1-methyl-5-({[1-methyl-5-
({[2-(4-morpholinyl)ethyl]amino}carbonyl)-1H-pyrrol-3-yl]amino}
carbonyl)-1H-pyrrol-3-yl]-1H-pyrrole-2-carboxamide 4
Brown solid (26 mg, 38%) with no distinct melting point. 1H
NMR (DMSO-d6): 10.02 (1H, s), 9.91 (1H, s), 9.89 (1H, s), 9.52 (1H,
br), 8.20 (1H, t, J ¼ 5.5 Hz), 8.13 (1H, d, J ¼ 1.7 Hz), 7.21 (1H, d,
J¼ 1.7 Hz), 7.19 (1H, s), 7.18 (1H, d, J¼ 1.7 Hz), 7.06 (1H, d, J¼ 1.7 Hz),
7.00 (1H, d, J ¼ 1.7 Hz), 6.92 (1H, d, J ¼ 1.7 Hz), 4.02e3.99 (2H, m),
3.847 (3H, s), 3.845 (3H, s), 3.82 (3H, s), 3.72e3.13 (10H, m). IR
(KBr): 1665, 1550, 1290, 1200, 1131 cm1. HRFABMS: found:
525.2565 calculated for C25H33N8O5 525.2574.
4.3.13. 2-{[(4-{[(4-{[Imino(4-methoxy-2-pyridinyl)methyl]amino}-
1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-pyrrol-2-
yl)carbonyl]amino}-5-isopropyl-N-[2-(4-morpholinyl)ethyl]-1,3-
thiazole-4-carboxamide 5
White solid (20mg, 32%) with no distinct melting point. 1HNMR
(DMSO-d6): 12.05 (1H, s), 11.12 (1H, s), 10.11 (1H, s), 9.78 (2H, s &
br), 8.83 (1H, s), 8.08 (1H, br), 7.59 (1H, t, J ¼ 7.9 Hz), 7.46e7.29 (6H,
m), 7.08 (1H, d, J¼ 1.7 Hz), 4.20 (1H, septet, J¼ 6.9 Hz), 4.10 (2H, m),
3.95 (3H, s), 3.90 (3H, s), 3.88 (3H, s), 365e3.12 (10H, m),1.29 (6H, d,
J ¼ 6.9 Hz). IR (KBr): 1665, 1549, 1273, 1200, 1134 cm1.HRFABMS:
found: 676.3032 calculated for C33H42O5N9S 676.3030.
4.3.14. 5,6-Dichloro-N-[5-({[5-({[5-({[3-(dimethylamino)propyl]
amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-
isopropyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-
yl]nicotinamide 6
Pale yellow solid (51 mg, 46%) after freeze-drying. 1H NMR
(DMSO-d6): 10.67 (1H, s), 10.00 (1H, s), 9.93 (1H, s), 9.26 (1H, br),
8.89 (1H, d, J¼ 2.1 Hz), 8.59 (1H, d, J¼ 2.1 Hz), 8.14 (1H, t, J¼ 6.4 Hz),
7.42 (1H, d, J¼ 1.7 Hz), 7.34 (1H, d, J¼ 1.4 Hz), 7.17 (1H, d, J¼ 1.4 Hz),
7.11 (1H, d, J¼ 1.7 Hz), 5.98 (1H, d, J¼ 1.7 Hz), 8.95 (1H, d, J¼ 1.7 Hz),
5.44 (1H, quintet, J ¼ 6.7 Hz), 3.89 (3H, s), 3.81 (3H, s), 3.25 (2H, q,
J ¼ 6.1 Hz), 3.07 (2H, m), 2.79 (6H, d, J ¼ 4.1 Hz), 1.84 (2H, quintet,
J ¼ 8.0 Hz), 1.38 (6H, d, J ¼ 6.7 Hz). IR (KBr): 1650, 1582, 1529, 1439,
1406, 1250, 1200,1131 cm1. HRFABMS: found: 670.2483 calculated
for C31H38N9O4
35Cl2 670.2423.
4.3.15. N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-
methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-
yl]-4-{[imino(3-methoxyphenyl)methyl]amino}-1-methyl-1H-
pyrrole-2-carboxamide7
Prepared as per [19].
4.3.16. N-[1-Methyl-5-({[1-methyl-5-({[1-methyl-5-({[3-(4-
morpholinyl)propyl]amino}carbonyl)-1H-pyrrol-3-yl]amino}
carbonyl)-1H-pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]-3-
isoquinolinecarboxamide 8 (synthesis also reported in [21])
Yellow solid (47 mg, 55%) with no distinct melting point (after
the puriﬁcation by HPLC). 1H NMR (DMSO-d6): 10.81 (1H, s), 9.98
(1H, s), 9.91 (1H, s), 9.64 (1H, br), 9.45 (1H, s), 8.64 (1H, s), 8.29 (1H,
d, J ¼ 8.0 Hz), 8.24 (1H, d, J ¼ 8.0 Hz), 8.16 (1H, t, J ¼ 6.0 Hz), 7.92
(1H, dt, J ¼ 1.2 Hz & J ¼ 7.2 Hz), 7.83 (1H, dt, J ¼ 1.2 Hz & J ¼ 7.2 Hz),
7.44 (1H, d, J ¼ 1.7 Hz), 7.30 (1H, d, J ¼ 1.7 Hz), 7.25 (1H, d,
J¼ 1.7 Hz), 7.18 (1H, d, J¼ 1.7 Hz), 7.09 (1H, d, J¼ 1.7 Hz), 6.96 (1H, d,
J¼ 1.7 Hz), 4.05e4.00 (2H, m), 3.91 (3H, s), 3.87 (3H, s), 3.82 (3H, s),
3.75e3.06 (10H, m), 1.88 (2H, quintet, J ¼ 6.8 Hz). IR (KBr): 1665,
1550, 1290, 1200, 1131 cm1. HRFABMS: found: 666.3173 calculated
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for C35H40N9O5 666.3152.
4.3.17. 4-{[(4-{[imino(3-methoxyphenyl)methyl]amino}-1-methyl-
1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-N-[1-methyl-5-({[3-(4-
morpholinyl)propyl]amino}carbonyl)-1H-pyrrol-3-yl]-1H-pyrrole-
2-carboxamide 9
Prepared as per [19].
4.3.18. N-[3-(Dimethylamino)propyl]-5-isopentyl-2-({[1-methyl-4-
({4-[(E)-2-(3-quinolinyl)ethenyl]benzoyl}amino)-1H-pyrrol-2-yl]
carbonyl}amino)-1,3-thiazole-4-carboxamide 10
Prepared as per [19].
4.3.19. N-[3-(dimethylamino)propyl]-5-isopentyl-2-({[4-({4-[(E)-
2-(3-methoxyphenyl)ethenyl]benzoyl}amino)-1-methyl-1H-pyrrol-
2-yl]carbonyl}amino)-1,3-thiazole-4-carboxamide 11
Prepared as per [19].
4.3.20. N-[3-(Dimethylamino)propyl]-5-isopentyl-2-({[4-({3-[(E)-
2-(3-methoxyphenyl)ethenyl]benzoyl}amino)-1-methyl-1H-pyrrol-
2-yl]carbonyl}amino)-1,3-thiazole-4-carboxamide 12
White solid (26 mg, 28%), with no distinct melting point. 1H
NMR (DMSO-d6): 12.13 (1H, s), 10.48 (1H, s), 9.51 (1H, br), 8.15 (1H,
br), 7.96 (1H, t, J ¼ 6.1 Hz), 7.84 (2H, q, J ¼ 7.8 Hz), 7.55 (2H, m), 7.45
(1H, d, J ¼ 1.7 Hz), 7.37e7.29 (3H, m), 7.23e7.21 (2H, m), 6.89e6.87
(1H, m), 3.93 (3H, s), 3.81 (3H, s), 3.36 (2H, t, J¼ 6.5 Hz), 3.22 (2H, t,
J ¼ 7.7 Hz), 3.11e3.05 (2H, m), 2.79 (6H, d, J ¼ 4.8 Hz), 1.91(2H, t,
J ¼ 7.7 Hz), 1.63e1.50 (3H, m), 0.93 (6H, d, J ¼ 6.4 Hz). IR (KBr): IR
(KBr): 1682, 1641, 1583, 1540, 1464, 1435, 1404, 1266, 1202,
1134 cm1. HRFABMS: Found: 657.3226 Calculated for C36H45O4N6S
657.3218.
4.3.21. N-[3-(dimethylamino)propyl]-5-isopentyl-2-[({1-methyl-4-
[({1-methyl-4-[(E)-2-(4-nitrophenyl)ethenyl]-1H-pyrrol-2-yl}
carbonyl)amino]-1H-pyrrol-2-yl}carbonyl)amino]-1,3-thiazole-4-
carboxamide 13
Orange solid (17 mg, 18%), with no distinct melting point. 1H
NMR (DMSO-d6): 12.09 (1H, s), 10.15 (1H, s), 9.41 (1H, br), 8.19 (2H,
d, J¼ 8.9 Hz), 7.99 (1H, t, J¼ 6.1 Hz), 7.76 (2H, d, J¼ 8.9 Hz), 7.46 (1H,
d, J ¼ 1.7 Hz), 7.41 (2H, dd, J ¼ 1.7 Hz & d, J ¼ 16.2 Hz), 7.33 (1H, d,
J¼ 1.7 Hz), 7.27 (1H, d, J¼ 1.7 Hz), 6.96 (1H, d, J¼ 16.2 Hz), 3.90 (6H,
s), 3.36 (2H, q, J¼ 6.5 Hz), 3.21 (2H, t, J ¼ 7.7 Hz), 3.11e3.06 (2H, m),
2.79 (6H, d, J ¼ 4.8 Hz), 1.91 (2H, t, J ¼ 6.8 Hz), 1.63e1.49 (3H, m),
0.93 (6H, d, J ¼ 6.4 Hz). IR (KBr): 1680, 1645, 1580, 1544, 1461, 1440,
1414, 1269, 1206, 1133 cm1. HRFABMS: Found: 675.3082 Calcu-
lated for C34H43O5N8S 675.3072.
4.3.22. N-[1-Methyl-5-({[1-methyl-5-({[2-(4-morpholinyl)ethyl]
amino}carbonyl)-1H-pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]-
3-isoquinolinecarboxamide 14
Yellow solid (85 mg, 54%) with no distinct melting point. 1H
NMR (DMSO-d6): 10.81 (1H, s), 9.98 (1H, s), 9.63 (1H, s), 9.44 (1H,
br), 8.63 (1H, s), 8.29 (1H, d, J ¼ 8.0 Hz), 8.24 (1H, d, J ¼ 8.0 Hz
overlapped with 1H broad), 7.92 (1H, t, J ¼ 7.2 Hz), 7.85 (1H, t,
J¼ 7.2 Hz), 7.43 (1H, d, J¼ 1.7 Hz), 7.30 (1H, d, J¼ 1.7 Hz), 7.22 (1H, d,
J ¼ 1.7 Hz), 7.02 (1H, d, J ¼ 1.7 Hz), 4.03 (2H, m), 3.88 (3H, s), 3.83
(3H, s), 3.67 (2H, t, J ¼ 12.0 Hz), 3.05 (4H, m), 3.28 (2H, m), 3.13 (2H,
m). IR (KBr): 1672, 1584, 1539, 1463, 1436, 1405, 1268, 1201,
1136 cm1. HRFABMS: found: 530.2515 calculated for C28H32O4N7
530.2516.
4.3.23. N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-
methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-
3-isoquinolinecarboxamide 15
Yellow solid (88 mg, 54%) with no distinct melting point. 1H
NMR (DMSO-d6): 10.80 (1H, s), 9.95 (1H, s), 9.44 (1H, s), 8.63 (1H, s),
8.29 (1H, d, J ¼ 8.0 Hz), 8.23 (1H, d, J ¼ 8.0 Hz), 8.15 (1H, t,
J¼ 5.6 Hz), 7.91 (1H, t, J¼ 7.2 Hz), 7.83 (1H, t, J¼ 7.2 Hz), 7.43 (1H, s),
7.28 (1H, s), 7.19 (1H, s), 6.95 (1H, s), 3.85 (3H, s), 3.82 (3H, s), 3.26
(2H, q, J ¼ 6.0 Hz), 3.08 (2H, m), 2.80 (6H, d, J ¼ 4.8 Hz), 1.85 (2H,
quintet, J ¼ 8.0 Hz). IR (KBr): 1674, 1584, 1538, 1469, 1437, 1405,
1267, 1200, 1140 cm1. HRFABMS: found: 502.2566 calculated for
C27H32O3N7 502.2567.
4.3.24. 4-({4-[(E)-2-(1,3-benzoxazol-2-yl)ethenyl]benzoyl}amino)-
1-methyl-N-[1-methyl-5-({[2-(4-morpholinyl)ethyl]amino}
carbonyl)-1H-pyrrol-3-yl]-1H-pyrrole-2-carboxamide 16
Yellow solid (6 mg, 7%) with no distinct melting point. 1H NMR
(DMSO-d6): 10.42 (1H, s), 9.98 (2H, s& br), 8.25 (1H, br), 8.03 (2H, d,
J¼ 8.4 Hz), 7.97 (2H, d, J¼ 8.4 Hz), 7.92 (1H, d, J¼ 16.3 Hz), 7.76 (2H,
t, J¼ 7.1 Hz), 7.50 (1H, d, J¼ 16.3 Hz), 7.42 (2H, t, J¼ 7.1 Hz), 7.35 (1H,
d, J¼ 1.6 Hz), 7.22 (1H, d, J¼ 1.6 Hz), 7.13 (1H, d, J¼ 1.6 Hz), 6.99 (1H,
d, J¼ 1.6 Hz), 4.02e3.99 (2H, m), 3.88 (3H, s), 3.83 (3H, s), 3.72e3.64
(2H, m), 3.55e3.54 (4H, m), 3.27 (2H, m), 3.14 (2H, m). IR (KBr):
3427, 1673, 1588, 1402, 1253, 1202, 1174, 832, 720 cm1. HRFABMS:
found: 622.2775 calculated for C34H36O5N7 622.2772.
4.3.25. N-[5-({[3-(dimethylamino)propyl]amino}carbonyl)-1-
methyl-1H-pyrrol-3-yl]-4-{[(4-{[imino(3-isoquinolinyl)methyl]
amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-
pyrrole-2-carboxamide 17
Yellow solid (26 mg, 41%) with no distinct melting point. 1H
NMR (DMSO-d6): 10.02 (1H, s), 9.91 (1H, s), 9.60 (1H, s), 8.91 (1H, s),
8.40 (1H, d, J ¼ 8.1 Hz), 8.20 (1H, d, J ¼ 8.1 Hz), 8.03 (1H, t,
J¼ 8.9 Hz), 7.98 (1H, t, J¼ 8.9 Hz), 7.32 (1H, d, J¼ 1.7 Hz), 7.26 (1H, d,
J¼ 1.7 Hz), 7.16 (1H, d, J¼ 1.7 Hz), 7.11 (1H, d, J¼ 1.7 Hz), 7.08 (1H, d,
J¼ 1.7 Hz), 6.95 (1H, d, J¼ 1.7 Hz), 3.97 (3H, s), 3.86 (3H, s), 3.81 (3H,
s), 3.24 (2H, t, J ¼ 6.4 Hz), 3.07 (2H, m), 2.79 (6H, s), 1.84 (2H,
quintet, J ¼ 7.6 Hz). IR (KBr): 1675, 1582, 1545, 1467, 1436, 1405,
1263, 1202, 1134, 802, 720 cm1. HRFABMS: found: 623.3202
calculated for C33H39O3N10 623.3207.
4.3.26. N-[5-({[4-({[3-(Dimethylamino)propyl]amino}carbonyl)-5-
isopentyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-
yl]-3-isoquinolinecarboxamide 18
Prepared as per [19].
4.3.27. N-[3-(Dimethylamino)propyl]-2-{[(4-{[(4-{[imino(3-
isoquinolinyl)methyl]amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]
amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-5-isopentyl-1,3-
thiazole-4-carboxamide 19
Prepared as per [19].
4.3.28. 5-isopentyl-2-({[1-methyl-4-({4-[(E)-2-(2-naphthyl)
ethenyl]benzoyl}amino)-1H-pyrrol-2-yl]carbonyl}amino)-N-[2-(4-
morpholinyl)ethyl]-1,3-thiazole-4-carboxamide 20
Prepared as per [19].
4.3.29. 5-isopentyl-2-[({1-methyl-4-[({1-methyl-4-[(E)-2-(4-
nitrophenyl)ethenyl]-1H-pyrrol-2-yl}carbonyl)amino]-1H-pyrrol-2-
yl}carbonyl)amino]-N-[2-(4-morpholinyl)ethyl]-1,3-thiazole-4-
carboxamide 21
Prepared as per [22].
4.3.30. 1-methyl-N-[1-methyl-5-({[2-(4-morpholinyl)ethyl]amino}
carbonyl)-1H-pyrrol-3-yl]-4-[(4-{(E)-2-[4-(triﬂuoromethyl)phenyl]
ethenyl}benzoyl)amino]-1H-pyrrole-2-carboxamide 22
Pale yellow solid (29.6 mg, 32%) with no distinct melting point.
1H NMR (DMSO-d6): 10.38 (1H, s), 10.01 (1H, s), 9.65 (1H, br), 8.26
(1H, t, J ¼ 5.7 Hz), 8.01 (2H, d, J ¼ 8.5 Hz), 7.88 (2H, d, J ¼ 8.2 Hz),
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7.81 (2H, d, J¼ 8.6 Hz), 7.78 (2H, d, J¼ 8.6 Hz), 7.52 (2H, s), 7.35 (1H,
d, J¼ 1.8 Hz), 7.23 (1H, d, J¼ 1.8 Hz), 7.13 (1H, d, J¼ 1.8 Hz), 7.06 (1H,
d, J¼ 1.8 Hz), 4.03 (2H, m), 3.88 (3H, s), 3.84 (3H, s), 3.69e3.15 (10H,
m). IR (KBr): 1647, 1580, 1536, 1432, 1404, 1259, 1202, 1127 cm1.
HRFABMS: Found: 649.2747 calculated for C34H36O4N6F3 649.2750.
4.3.31. 5-isopentyl-2-({[1-methyl-4-({4-[(E)-2-(2-quinolinyl)
ethenyl]benzoyl}amino)-1H-pyrrol-2-yl]carbonyl}amino)-N-[2-(4-
morpholinyl)ethyl]-1,3-thiazole-4-carboxamide 23
Prepared as per [19].
4.3.32. 1-Methyl-N-[1-methyl-5-({[2-(4-morpholinyl)ethyl]amino}
carbonyl)-1H-pyrrol-3-yl]-4-({4-[(E)-2-(4-pyridinyl)ethenyl]
benzoyl}amino)-1H-pyrrole-2-carboxamide 24
Prepared as per [19].
4.3.33. 4-[(2,4-Dichlorobenzoyl)amino]-1-methyl-N-[1-methyl-5-
({[1-methyl-5-({[3-(4-morpholinyl)propyl]amino}carbonyl)-1H-
pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]-1H-pyrrole-2-
carboxamide 25
Brown solid (45 mg, 51%) with no distinct melting point. 1H
NMR (DMSO-d6): 10.48 (1H, s), 9.96 (1H, s), 9.89 (1H, s), 9.67 (1H,
br), 8.15 (1H, t, J ¼ 5.8 Hz), 7.74 (1H, d, J ¼ 1.7 Hz), 7.54 (2H, m), 7.27
(1H, d, J¼ 1.7 Hz), 7.23 (1H, d, J¼ 1.7 Hz), 7.17 (1H, d, J¼ 1.7 Hz), 7.06
(1H, d, J ¼ 1.7 Hz), 7.02 (1H, d, J ¼ 1.7 Hz), 6.95 (1H, d, J ¼ 1.7 Hz),
3.97e3.89 (2H, m), 3.90 (3H, s), 3.84 (3H, s), 3.81 (3H, s), 3.71e3.64
(2H, m), 3.61e3.26 (2H, m), 3.26 (2H, q, J ¼ 6.0 Hz), 3.12e3.06 (4H,
m), 1.90e1.85 (2H, quintet, J ¼ 7.1 Hz). IR (KBr): 1665, 1550, 1290,
1200, 1131 cm1. HRFABMS: found: 683.2275 calculated for
C32H37
35Cl2N8O5 683.2264.
4.3.34. 4-({4-[(E)-2-(4-ﬂuorophenyl)ethenyl]benzoyl}amino)-1-
methyl-N-[1-methyl-5-({[2-(4-morpholinyl)ethyl]amino}carbonyl)-
1H-pyrrol-3-yl]-1H-pyrrole-2-carboxamide 26
Yellow solid after freeze drying (54 mg, 63%) with no distinct
melting point. 1H NMR (DMSO-d6): 10.32 (1H, s), 9.98 (1H, s), 9.54
(1H, br), 8.23 (1H, t, J ¼ 5.6 Hz), 7.97 (2H, d, J ¼ 8.4 Hz), 7.74 (2H, d,
J ¼ 8.4 Hz), 7.71e7.68 (2H, m), 7.43 (1H, d, J ¼ 23.2 Hz), 7.39e7.21
(5H, m), 7.12 (1H, d, J¼ 1.8 Hz), 7.01 (1H, d, J¼ 1.8 Hz), 4.03 (2H, m),
3.88 (3H, s), 3.84 (3H, s), 3.69e3.15 (10H, m). IR (KBr): 1647, 1580,
1536, 1432, 1404, 1259, 1202, 1127 cm1. HRFABMS: Found:
599.2785 calculated for C33H36O4N6F 599.2782.
4.3.35. 4-({4-[(E)-2-(3-ﬂuorophenyl)ethenyl]benzoyl}amino)-1-
methyl-N-[1-methyl-5-({[2-(4-morpholinyl)ethyl]amino}carbonyl)-
1H-pyrrol-3-yl]-1H-pyrrole-2-carboxamide 27
Pale yellow solid (41 mg, 45%) with no distinct melting point. 1H
NMR (DMSO-d6): 10.34 (1H, s), 9.98 (1H, s), 9.58 (1H, br), 8.24 (1H,
t, J ¼ 5.7 Hz), 7.99 (2H, d, J ¼ 8.5 Hz), 7.76 (2H, d, J ¼ 8.5 Hz),
7.54e7.44 (3H, m), 7.42 (2H, s), 7.34 (1H, d, J ¼ 1.8 Hz), 7.22 (1H, d,
J ¼ 1.8 Hz), 7.17e7.11 (2H, m), 7.01 (1H, d, J ¼ 1.8 Hz), 4.03 (2H, m),
3.88 (3H, s), 3.84 (3H, s), 3.69e3.15 (10H, m). IR (KBr): 1647, 1580,
1536, 1432, 1404, 1259, 1202, 1127 cm1. HRFABMS: Found:
599.2790 calculated for C33H36O4N6F 599.2782.
4.3.36. 4-({4-[(E)-2-(2,1,3-benzothiadiazol-5-yl)ethenyl]benzoyl}
amino)-1-methyl-N-[1-methyl-5-({[2-(4-morpholinyl)ethyl]amino}
carbonyl)-1H-pyrrol-3-yl]-1H-pyrrole-2-carboxamide 28
Yellow solid (12mg,13%) with no distinct melting point. 1HNMR
(DMSO-d6): 10.39 (1H, s), 10.01 (1H, s), 9.55 (1H, br), 10.45e10.38
(3H, m), 10.34 (1H, d, J ¼ 9.0 Hz), 10.22e10.20 (2H, d, J ¼ 8.4 Hz),
10.04 (2H, d, J ¼ 8.4 Hz), 9.87 (2H, s), 9.55 (1H, d, J ¼ 1.7 Hz), 9.42
(1H, d, J¼ 1.7 Hz), 9.34 (1H, d, J¼ 1.7 Hz), 9.21 (1H, br), 4.03 (2H, m),
3.88 (3H, s), 3.84 (3H, s), 3.69e3.15 (10H, m). IR (KBr): 1647, 1580,
1536, 1432, 1404, 1259, 1202, 1127 cm1. HRFABMS: Found:
639.2498 calculated for C33H35O4N8S 639.2502.
4.3.37. 4-({4-[(E)-2-(2,1,3-benzoxadiazol-5-yl)ethenyl]benzoyl}
amino)-1-methyl-N-[1-methyl-5-({[2-(4-morpholinyl)ethyl]amino}
carbonyl)-1H-pyrrol-3-yl]-1H-pyrrole-2-carboxamide 29
Yellow solid (30 mg, 30%) with no distinct melting point. 1H
NMR (DMSO-d6): 10.40 (1H. s), 10.01 (1H, s), 9.53 (1H, br), 8.25 (1H,
t, J ¼ 5.9 Hz), 8.11 (3H, s), 8.03 (2H, d, J ¼ 8.4 Hz), 7.83 (2H, d,
J ¼ 8.4 Hz), 7.73 (1H, d, J ¼ 16.4 Hz), 7.64 (1H, d, J ¼ 16.4 Hz), 7.35
(1H, d, J¼ 1.7 Hz), 7.22 (1H, d, J¼ 1.7 Hz), 7.14 (1H, d, J¼ 1.7 Hz), 7.02
(1H, d, J ¼ 1.7 Hz), 4.03 (2H, m), 3.88 (3H, s), 3.84 (3H, s), 3.69e3.15
(10H, m). IR (KBr): 1647, 1580, 1536, 1432, 1404, 1259, 1202,
1127 cm1. HRFABMS: Found: 623.2728 calculated for C33H35O5N8
623.2730.
4.3.38. 2-[(E)-2-(4-Methoxyphenyl)ethenyl]-N-[1-methyl-5-({[1-
methyl-5-({[2-(4-morpholinyl)ethyl]amino}carbonyl)-1H-pyrrol-3-
yl]amino}carbonyl)-1H-pyrrol-3-yl]-6-quinolinecarboxamide 30
Prepared as per [19].
4.3.39. N-[1-methyl-5-({[1-methyl-5-({[2-(4-morpholinyl)ethyl]
amino}carbonyl)-1H-pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]-
2-{(E)-2-[4-(methylsulfanyl)phenyl]ethenyl}-6-
quinolinecarboxamide 31
Prepared as per [19].
4.3.40. 6-{(E)-2-[4-(Dimethylamino)phenyl]ethenyl}-N-[1-methyl-
5-({[1-methyl-5-({[2-(4-morpholinyl)ethyl]amino}carbonyl)-1H-
pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]nicotinamide 32
Red solid (69 mg, 38%) with no distinct melting point. 1H NMR
(DMSO-d6): 10.44 (1H, s), 9.99 (1H, s), 9.54 (1H, br), 9.05 (1H, d,
J ¼ 2.0 Hz), 8.26e8.22 (2H, m), 7.74 (1H, d, J ¼ 16.0 Hz), 7.64 (1H, d,
J¼ 8.4 Hz), 7.55 (1H, s), 7.53 (1H, s), 7.35 (1H, d, J¼ 1.7 Hz), 7.22 (1H,
d, J¼ 1.7 Hz), 7.14e7.09 (2H, m), 7.02 (1H, d, J ¼ 1.7 Hz), 6.78 (1H, s),
6.76 (1H, s), 4.04e4.01 (2H, m), 3.89 (3H, s), 3.85 (3H, s), 3.70e3.55
(6H, m), 3.30e3.29 (2H, m), 3.16e3.13 (2H, m), 2.98 (6H, s). IR (KBr):
721, 804, 1130, 1173, 1289, 1368, 1435, 1530, 1576, 1665 cm1.
HRFABMS: Found: 623.3209 calculated for C33H39O3N10 623.3201.
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